View Older Stories View More Recent Stories
-
Gilead Sciences (GILD) call put ratio 1.2 calls to 1 put as share price up 1.4%
-
Exact Sciences (EXAS), Gilead Sciences (GILD) Spike Higher
-
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
-
Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
-
Gilead Sciences (GILD) Yeztugo Label 'Looks Clean' - Mizuho
-
Gilead Sciences (GILD) Yeztugo approval a 'major win' - BMO Capital
-
Gilead Sciences (GILD): Yeztugo Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Gilead Sciences (GILD) PT Raised at RBC Capital Following Patient Survey
-
FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer
-
Gilead Sciences shares hit after HIV studies placed on hold by FDA
-
RBC Capital on Gilead Sciences (GILD): 'We Would Look for a Better Entry Point'
-
Gilead Sciences (GILD) Says FDA Placed Cilnical Hold On Hiv Treatment Trials
-
Gilead Sciences (GILD) call put ratio 1 call to 1.3 puts as share price near upper end of range
-
Morgan Stanley Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) Shares Drop To Session Low, Down Over 3%
-
Citi Reiterates Buy Rating on Gilead Sciences (GILD)
-
What can get the U.S. large-cap pharma sector to work?
-
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study
-
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing
-
Gilead Sciences (GILD) U.S. Investment to Create $43B in Value to U.S. Economy
-
Gilead Sciences (GILD) call put ratio 1 call to 4.4 puts
-
Will the HIV/AIDS payer landscape change?
-
Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
-
Gilead Sciences (GILD) Tops Q1 EPS by 4c; maintains guidance
-
Gilead Sciences (GILD) call put ratio 1 call to 1 put into quarter results
-
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Bernstein on Gilead Sciences (GILD): 'TNBC is a Meaningful Opportunity'
-
Cantor Fitzgerald Assumes Gilead Sciences (GILD) at Overweight
-
Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Pharma stocks slide after Trump signals tariffs on sector
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'
-
BMO Capital Reiterates Outperform on Gilead Sciences (GILD) Amid 'Potential HHS HIV Funding Cuts'
-
Gilead Sciences (GILD) call put ratio 1 call to 2.5 puts amid price movement
-
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more
-
Gilead Sciences (GILD) Weakness Tied to Reports Trump Admin Planning Major Funding Cuts for HIV Prevention
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
Bernstein SocGen Group Reiterates Outperform Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) Presents New HIV Treatment and Cure Research Data
-
Gilead Sciences (GILD) Presents First Clinical Data for Investigational Once-Yearly Lenacapavir for HIV Prevention
-
Gilead Sciences (GILD) PT Raised to $132 at Oppenheimer
-
Morgan Stanley Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD): U.S. FDA Accepts New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
-
Arcus Biosciences (RCUS) Retains Rights to Casdatifan, and Announces Pricing of $150 Million Common Stock Offering
-
Gilead Sciences (GILD) PT Raised to $100 at TD Cowen Following 'Strong Top & Bottom Beat'
-
RBC: 'Gilead Sciences (GILD) Exits 2024 On Strong Note'; PT Raised
-
Gilead Sciences (GILD) PT Raised to $115 at BMO Capital; 'More Growth Coming in 25'

